About - Flosonics Medical

About Flosonics Medical

Patient centered Clinician led

Flosonics Medical was founded on the mission of improving patient care through technology enabled solutions and services that clinicians love.

With deep expertise in ultrasound technology and critical care medicine, Flosonics Medical has developed a wireless, wearable Doppler ultrasound system to support clinicians’ decisions regarding fluid resuscitation and management.

Board of Directors

Joseph Eibl (PhD)

Director & CEO

Joseph Eibl (PhD)

Director & CEO

Dr. Eibl is responsible for the growth and development of technology, intellectual property and business strategy. Dr. Eibl holds a PhD in Biomolecular Sciences and he has conducted postdoctoral training in the field of bioengineering.

Paul Magnin (PhD)

Chairman

Paul Magnin (PhD)

Chairman

Paul Magnin spent 17 years as a key contributor to Hewlett-Packard’s Ultrasound Imaging business. He was the R&D Manager of Hewlett-Packard’s Imaging Systems business from 1992 through 1995 and General Manager from 1996 through 1998. From 1999 through 2003, Dr. Magnin was the President and CEO of LightLab Imaging.

Dan Kidle

Director

Dan Kidle

Director

Dan identifies promising investment opportunities across Arboretum’s sectors of interest, with particular emphasis on life science tools. He also works closely with portfolio companies to support strategic decision-making, fundraising efforts, and financial analysis. Since joining Arboretum in 2011, Dan has undertaken primary due diligence responsibilities on more than a dozen of Arboretum’s new and follow-on investments including NeuMoDx, Rethink, Strata Oncology, and SI-BONE. Dan currently serves as a board director for Swift Biosciences, Dropworks, JUMPCODE Genomics and Flosonics Medical and previously for IntelliCyt, which was acquired in 2016. Dan was a recipient of the National Venture Capital Association’s Rising Star Award in 2020. Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan currently serves on the Investment Advisory Board for the Michigan Biomedical Venture Fund at the University of Michigan. Dan earned a BBA and an MBA from the Ross School of Business at the University of Michigan.

Sam Ifergan

Director

Sam Ifergan

Director

Sam has over 20 years of entrepreneurial, technology and venture capital experience. As Managing Partner of the iGan Partners team, he is involved in the evaluation, structuring, execution, and monitoring of iGan’s investments. Sam has been extensively involved with several companies, often serving as CEO, particularly in the early stages of each company’s development. Prior to founding iGan Partners, he co-founded several companies including Visualsonics, Tri-Link Technologies and Brighter Minds.

Damian Lamb

Director

Damian Lamb

Director

Mr. Lamb is co-Founder and Managing Director of Genesys Capital. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $160 million across 29 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Fusion Pharmaceuticals, Profound Medical Inc. (TSX: PRN) and the Centre for Probe Development and Commercialization at McMaster University.

Kevin King

Director

Kevin King

Director

Kevin King is an accomplished President, CEO and Director with a demonstrated track record of leading public and private companies to new levels of growth, profitability and commercial success.

Mary Jo Gorman

Director

Mary Jo Gorman

Director

Mary Jo Gorman brings established leadership capabilities as an independent director, chief executive, and healthcare founder. She has a proven record of launching and growing companies that created value for investors in the health care services sector.